ArticleFrontiers in immunology2026
High baseline CD317 expression on T cells predicts favorable anifrolumab response in systemic lupus erythematosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anifrolumab (ANI), a monoclonal antibody blocking the type I interferon (IFN) receptor, is approved for systemic lupus erythematosus (SLE); yet real-world responses vary. We aimed to identify biomarkers predicting clinical response to ANI in SLE. Methods: We prospectively enrolled patients with SLE who initiated ANI and evaluated immune cell subsets and type I IFN-associated markers by flow cytometry with respect to clinical response to ANI. Clinical response at 6 months was classified into responders and non-responders based on two criteria: achievement of a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response and successful glucocorticoid tapering. Results: Of the 31 patients analyzed, 15 were responders and 16 were non-responders. Among the ten biomarkers that showed significant changes in responders, four - CD317 expression on T cells, CD317 expression on B cells, CD169 expression on monocytes, and T-peripheral-helper-cell frequency - were already higher at baseline in responders than in non-responders. Baseline CD317 expression on T cells showed the highest discriminative power in predicting 6-month response, separating responders from non-responders with an AUC of 0.89, surpassing the four-gene IFN gene signature (IFNGS) measured by quantitative PCR (qPCR) (DeLong's test, Conclusions: This study demonstrates that higher baseline CD317 expression on T cells is associated with a favorable clinical response to ANI and predicts this response more accurately than the previously proposed IFNGS in patients with SLE. These findings identify CD317 as a promising and practical candidate biomarker to guide personalized treatment strategies in SLE, contingent upon further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.